ASTRAZENECA PHARMA INDIA
|
ASTRAZENECA PHARMA INDIA Last 5 Year Financial Ratios History
[Standalone]
| Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 64.60 | 39.72 | 24.64 | 37.32 | 28.88 |
| CEPS(Rs) | 70.58 | 46.22 | 31.42 | 45.37 | 36.32 |
| DPS(Rs) | 24.00 | 16.00 | 10.00 | 2.00 | 1.00 |
| Book NAV/Share(Rs) | 283.45 | 234.45 | 203.78 | 181.83 | 145.14 |
| Tax Rate(%) | 26.43 | 25.96 | 25.82 | 26.59 | 36.64 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 14.17 | 16.39 | 10.65 | 16.58 | 14.45 |
| EBIT Margin(%) | 16.95 | 13.37 | 10.38 | 15.69 | 13.78 |
| Pre Tax Margin(%) | 16.86 | 13.31 | 10.26 | 15.56 | 13.64 |
| PAT Margin (%) | 12.40 | 9.85 | 7.61 | 11.42 | 8.65 |
| Cash Profit Margin (%) | 13.55 | 11.47 | 9.70 | 13.88 | 10.87 |
| Performance Ratios | |||||
| ROA(%) | 13.35 | 9.37 | 6.65 | 11.31 | 10.57 |
| ROE(%) | 24.95 | 18.13 | 12.78 | 22.83 | 21.83 |
| ROCE(%) | 33.94 | 24.49 | 17.36 | 31.24 | 34.61 |
| Asset Turnover(x) | 1.08 | 0.95 | 0.87 | 0.99 | 1.22 |
| Sales/Fixed Asset(x) | 7.11 | 5.79 | 4.93 | 5.58 | 6.61 |
| Working Capital/Sales(x) | 2.26 | 2.23 | 2.17 | 2.59 | 3.88 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.14 | 0.17 | 0.20 | 0.18 | 0.15 |
| Receivable days | 36.53 | 35.03 | 38.57 | 37.62 | 35.61 |
| Inventory Days | 58.60 | 59.85 | 67.64 | 72.59 | 61.89 |
| Payable days | 131.27 | 214.92 | 220.48 | 246.52 | 229.92 |
| Valuation Parameters | |||||
| PER(x) | 82.35 | 81.76 | 103.71 | 80.66 | 82.80 |
| PCE(x) | 75.38 | 70.26 | 81.33 | 66.34 | 65.85 |
| Price/Book(x) | 18.77 | 13.85 | 12.54 | 16.55 | 16.48 |
| Yield(%) | 0.45 | 0.49 | 0.39 | 0.07 | 0.04 |
| EV/Net Sales(x) | 9.88 | 7.60 | 7.37 | 8.82 | 6.88 |
| EV/Core EBITDA(x) | 58.36 | 39.84 | 58.85 | 48.37 | 42.83 |
| EV/EBIT(x) | 57.96 | 56.54 | 70.72 | 55.96 | 49.75 |
| EV/CE(x) | 17.97 | 12.94 | 11.62 | 8.21 | 7.38 |
| M Cap / Sales | 10.27 | 8.09 | 7.93 | 9.25 | 7.19 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 29.17 | 24.50 | -0.98 | -2.19 | 14.21 |
| Core EBITDA Growth(%) | 14.66 | 89.44 | -31.94 | 10.94 | 52.63 |
| EBIT Growth(%) | 63.84 | 60.41 | -34.47 | 11.35 | 58.40 |
| PAT Growth(%) | 62.66 | 61.19 | -33.98 | 29.21 | 32.62 |
| EPS Growth(%) | 62.66 | 61.19 | -33.98 | 29.21 | 32.62 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | - | - | - | - | - |
| Current Ratio(x) | 2.23 | 1.93 | 1.95 | 1.84 | 1.59 |
| Quick Ratio(x) | 1.74 | 1.54 | 1.59 | 1.42 | 1.14 |
| Interest Cover(x) | 183.95 | 213.86 | 88.41 | 117.60 | 100.97 |
| Total Debt/Mcap(x) | - | - | - | - | - |
Compare Financial Ratios of peers of ASTRAZENECA PHARMA INDIA
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| ASTRAZENECA PHARMA INDIA | ₹17,245.8 Cr | 3.1% | -2.8% | 59.9% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹437,483.0 Cr | 0.4% | 5.1% | 64.6% | Stock Analytics | |
| DIVIS LABORATORIES | ₹136,472.0 Cr | 2.1% | 3.9% | 42.8% | Stock Analytics | |
| CIPLA | ₹130,171.0 Cr | -2.1% | 3.7% | 30.8% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹111,298.0 Cr | -2.9% | -3.7% | 20.1% | Stock Analytics | |
| ZYDUS LIFESCIENCES | ₹110,736.0 Cr | -1% | -13.6% | 81.7% | Stock Analytics | |
ASTRAZENECA PHARMA INDIA Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| ASTRAZENECA PHARMA INDIA | 3.1% |
-2.8% |
59.9% |
| SENSEX | -1.4% |
3.3% |
25.2% |
You may also like the below Video Courses
